Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM. Spurgeon SE, et al. Among authors: fletcher lb. J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7. J Pharmacol Exp Ther. 2013. PMID: 23220742 Free PMC article.
MET receptor sequence variants R970C and T992I lack transforming capacity.
Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM. Tyner JW, et al. Among authors: fletcher lb. Cancer Res. 2010 Aug 1;70(15):6233-7. doi: 10.1158/0008-5472.CAN-10-0429. Cancer Res. 2010. PMID: 20670955 Free PMC article.
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.
Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM. Tyner JW, et al. Among authors: fletcher lb. Cancer Res. 2013 Jan 1;73(1):285-96. doi: 10.1158/0008-5472.CAN-12-1906. Epub 2012 Oct 18. Cancer Res. 2013. PMID: 23087056 Free PMC article.
Novel Approaches for Systemic Mastocytosis.
Fletcher L, Borate U. Fletcher L, et al. Curr Opin Hematol. 2019 Mar;26(2):112-118. doi: 10.1097/MOH.0000000000000486. Curr Opin Hematol. 2019. PMID: 30694839 Review.
Cell Death Pathways in Lymphoid Malignancies.
Fletcher L, Nabrinsky E, Liu T, Danilov A. Fletcher L, et al. Curr Oncol Rep. 2020 Jan 27;22(1):10. doi: 10.1007/s11912-020-0874-3. Curr Oncol Rep. 2020. PMID: 31989308 Review.
IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H, Fletcher L, Traer E. McMurry H, et al. Curr Hematol Malig Rep. 2021 Apr;16(2):207-217. doi: 10.1007/s11899-021-00619-3. Epub 2021 Apr 30. Curr Hematol Malig Rep. 2021. PMID: 33939107 Review.
Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations.
Newell LF, Dunlap J, Gatter K, Bagby GC, Press RD, Cook RJ, Fletcher L, Leonard JT, Leong KM, Bubalo JS, Olyaei A, Deloughery TG, Maziarz RT, Maynard E, Orloff SL, Enestvedt CK. Newell LF, et al. Am J Transplant. 2021 Dec;21(12):3894-3906. doi: 10.1111/ajt.16635. Epub 2021 Jul 19. Am J Transplant. 2021. PMID: 33961341 Free article.
50 results